Pharmacotherapy in patients with ulcerative colitis;Medikamentöse Versorgung von Patienten mit Colitisulcerosa

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 7, 2011, Pages 820-826

  Scherer, M ^a,b   Hardt, J ^a,c   Blozik, E ^a,b   Preiss J C ^d   Bokemeyer, B ^e,f   Huppe A ^a   Raspe, H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF WUPPERTAL   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

health services research; pharmacological treatment; self reported data; ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; CORTICOSTEROID; LOPERAMIDE;

ALTERNATIVE MEDICINE; ARTICLE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE DURATION; DISEASE REGISTRY; FEMALE; GASTROENTEROLOGICAL PROCEDURES; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRESCRIPTION; QUESTIONNAIRE; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; COLITIS, ULCERATIVE; FEMALE; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; MALE; MESALAMINE; MIDDLE AGED; PRESCRIPTIONS; PREVALENCE; YOUNG ADULT;

EID: 79960593355     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1273276     Document Type: Article

References (22)

1. Hoffman J C., Zeitz M, Bischoff S C. et al. Diagnostik und Therapie der Colitis Ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen zusammen mit dem Kompetenznetz chronisch entzündliche Darmerkrankungen. Z Gastroenterol 2004 42 979-983 (Pubitemid 39625605)
2. Prenzler A, Mittendorf T, Conrad S et al. Die direkten Kosten der Versorgung von Patienten mit Morbus Crohn aus der Perspektive der Gesetzlichen Krankenversicherung. Z Gastroenterol 2009 47 659-666
3. Blumenstein I, Bock H, Weber C et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 2008 14 53-60 (Pubitemid 351196869)
4. Solberg I C., Lygren I, Jahnsen J et al. IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009 44 431-440
5. Hoffmann J C., Preiss J C., Autschbach F et al. S3-Leitlinie Diagnostik und Therapie des Morbus Crohn. Ergebnisse einer Evidenz-basierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zusammen mit dem Kompetenznetz Chronisch entzündliche Darmerkrankungen. Z Gastroenterol 2008 46 1094-1146
6. Lakatos P L. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol 2009 15 4234-4239
7. Reddy S I., Friedman S, Telford J J. et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005 100 1357-1361 (Pubitemid 40904362)
8. Zhu Q, Cao Q, Si J M. Quality of care for patients with inflammatory bowel disease in East China. World J Gastroenterol 2008 14 612-616 (Pubitemid 351320830)
9. Pieper C, Haag S, Gesenhues S et al. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders an evaluation study. BMC Health Serv Res 2009 9 17
10. Hardt J, Muche-Borowski C, Conrad S et al. Chronisch entzündliche Darmerkrankungen als multifokale Erkrankungen: körperliche und psychosoziale Probleme von Patienten mit CED. Ergebnisse eines Fragebogen-Surveys. Z Gastroenterol 2010 48 (3) 381-391. eFirst-Publikation 02.12.2009
11. Janke K H., Raible A, Bauer M et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004 19 343-53 (Pubitemid 38868300)
12. Janke K H., Klump B, Gregor M et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005 11 272-286 (Pubitemid 40439682)
13. Best W, Becktel J, Singelton J et al. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology 1976 70 439-444
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 298 82-86 (Pubitemid 19032930)
15. Tung J, Loftus E V., Freese D K. et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohns disease and ulcerative colitis. Inflamm Bowel Dis 2006 12 1093-1100 (Pubitemid 44847465)
16. Solberg I C., Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009 44 431-440
17. Faubion Jr W A., Loftus Jr E V., Harmsen W S. et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 255-260 (Pubitemid 32729372)
18. Hilsden R J., Verhoef M J., Best A et al. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol 2003 3 10
19. Wallace T M., Veldhuyzen, Zanten S J. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can J Gastroenterol 2001 15 21-28 (Pubitemid 32184287)
20. Rubin G van, Hungin A PS, Chinn D et al. Long-term aminosalicylate therapy is underused in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002 16 1889-1893 (Pubitemid 35253004)
21. Preiß J C., Schneidereit O, Höhne W et al. Ergebnisse einer kontrollierten Studie zur Implementierung klinischer Leitlinien mithilfe einer multimodalen Strategie im Bereich chronisch entzündlicher Darmerkrankungen. Z Gastroenterol 2009 47 P438
22. Raspe H, Conrad S, Muche-Borowski C. Evidenzbasierte und interdisziplinär konsentierte Versorgungspfade für Patientinnen/Patienten mit Morbus Crohn oder Colitis ulcerosa. Z Gastroenterol 2009 47 541-562